Progress in the Delivery of Therapeutic Oligonucleotides: Organ/Cellular Distribution and Targeted Delivery of OligonucleotidesIn Vivo
- 1 June 2003
- journal article
- review article
- Published by Mary Ann Liebert Inc in Antisense and Nucleic Acid Drug Development
- Vol. 13 (3) , 169-189
- https://doi.org/10.1089/108729003768247637
Abstract
Oligonucleotide (ODN) therapy is a powerful tool for modulation of gene expression in vivo. With advances in ODN chemistry and progress in formulation development, ODNs are becoming widely acceptable drugs. This review summarizes the current status and future trend of the in vivo application of ODN therapeutics, especially antisense ODNs. Here, we review the current understanding of the tissue/organ distribution and cellular uptake of ODN drugs administered parenterally or nonparenterally to intact animals. The problems and advantages inherent in the use of different delivery methods for the treatment of particular diseases are discussed in detail. Emphasis is placed on the most widely studied ODN analogs, the phosphorothioates (PS). Lessons learned from antisense PS studies have broad implications for ODN therapeutics in general.Keywords
This publication has 83 references indexed in Scilit:
- Potential roles of antisense technology in cancer chemotherapyOncogene, 2000
- Intercellular Adhesion Molecule-1 Suppression in Skin by Topical Delivery of Anti-Sense OligonucleotidesJournal of Investigative Dermatology, 2000
- Liposomes enhance delivery and expression of an RGD-oligolysine gene transfer vector in human tracheal cellsGene Therapy, 1998
- Therapeutic repair of mutated nucleic acid sequencesNature Biotechnology, 1998
- DNA antisense therapy for asthma in an animal modelNature, 1997
- Changes in Plasma Lipoprotein Cholesterol Levels by Antisense Oligodeoxynucleotides against Cholesteryl Ester Transfer Protein in Cholesterol-fed RabbitsPublished by Elsevier ,1996
- Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitroHepatology, 1996
- Antisense and the KidneyKidney and Blood Pressure Research, 1996
- Renal uptake of an 18-mer phosphorothioate oligonucleotideKidney International, 1995
- Pharmacokinetics of Antisense OligonucleotidesClinical Pharmacokinetics, 1995